These Analysts Slash Their Forecasts On Blackstone Following Downbeat Earnings

Blackstone Inc. (NYSE: BX) reported weaker-than-expected third-quarter earnings.

Blackstone Inc. (NYSE:BX) reported weaker-than-expected third-quarter earnings.

Blackstone reported segment revenues of $2.32 billion, down 10% Y/Y and missing the consensus of $2.51 billion. Distributable Earnings per share of $0.94 missed the consensus of $1.01.

Blackstone declared a quarterly dividend per share of $0.80, payable on November 6, 2023, to shareholders of record as of October 30, 2023.

Blackstone shares fell 0.1% to trade at $94.20 on Friday.

These analysts made changes to their price targets on Blackstone following earnings announcement.

  • Morgan Stanley lowered the price target on Blackstone from $125 to $120. Morgan Stanley analyst Michael Cyprys maintained an Overweight rating.
  • BMO Capital cut the price target on Blackstone from $97 to $94. BMO Capital analyst Rufus Hone maintained a Market Perform rating on the stock.
  • Wells Fargo slashed the price target on Blackstone from $118 to $113. Wells Fargo analyst Timothy O’Shea maintained an Overweight rating.

Check This Out: Over $8M Bet On Howard Hughes? Check Out These 3 Stocks Insiders Are Buying

Total
0
Shares
Related Posts
Read More

SELLAS Life Sciences Reports Data In Completed Phase 1 Study Of Galinpepimut-S Combined With Opdivo In Advanced Malignant Pleural Mesothelioma; Primary Endpoint Of Safety And Efficacy Endpoint Met With Clinical Activity And Increased Survival Observed

Primary Endpoint of Safety and Efficacy Endpoint Both Met with Clinical Activity and Increased Survival Observed   70.3 Weeks Median Overall Survival for Patients Treated with Combination Therapy

SLS